[HTML][HTML] An overview of in vitro and in vivo techniques for characterization of intranasal protein and peptide formulations for brain targeting

CYJ Wong, A Baldelli, O Tietz, J van der Hoven… - International Journal of …, 2024 - Elsevier
The surge in neurological disorders necessitates innovative strategies for delivering active
pharmaceutical ingredients to the brain. The non-invasive intranasal route has emerged as …

[HTML][HTML] Enhancing acute migraine treatment: exploring solid lipid nanoparticles and nanostructured lipid carriers for the nose-to-brain route

J Torres, R Silva, G Farias, JM Sousa Lobo… - Pharmaceutics, 2024 - mdpi.com
Migraine has a high prevalence worldwide and is one of the main disabling neurological
diseases in individuals under the age of 50. In general, treatment includes the use of oral …

[HTML][HTML] Development and Characterization of In Situ Gelling Nasal Cilostazol Spanlastics

M Salamah, M Budai-Szűcs, B Sipos, B Volk, G Katona… - Gels, 2025 - mdpi.com
Cilostazol (CIL), a BCS class II antiplatelet aggregation and vasodilator agent, is used for
cerebrovascular diseases to minimize blood–brain barrier dysfunction, white matter-lesion …

Advancing nasal formulation characterization: Considerations toward a robust and precise method to determine the mass fraction below 10 μm in nasal products

N Baltz, JO Svensson, M Skogevall… - Aerosol Science and …, 2024 - Taylor & Francis
The expanding role of the nasal route in drug administration for local and systemic
treatments has prompted the need for precise delivery methods to ensure efficacy and …